MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Avalyn Pharma Inc.

< Previous 1 2 Next >
News headline image
Avalyn Announces Upcoming Presentations on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the 22nd International Colloquium on Lung and Airway Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Presents Multiple Posters on AP01 for Pulmonary Fibrosis, Including MIST Phase 2b Trial Design and ATLAS Phase 1b Study Post-hoc Analyses, at ERS 2024
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Announces Initiation of its Global Phase 2b MIST Study of AP01 Inhaled Pirfenidone for Progressive Pulmonary Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Participate in Multiple Upcoming Investor Conferences
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Announces Upcoming Presentations on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the European Respiratory Society International Congress 2024
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Announces Initiation of Phase 1b Clinical Study for AP02, its Novel Inhaled Nintedanib
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Participate in Multiple Upcoming Investor Conferences
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Participate in Jefferies Global Healthcare Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Presents Clinical Data on AP01 for Pulmonary Fibrosis, Including Long-Term Efficacy and Imaging Biomarker Data, at ATS 2024
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Approach to Developing Novel Inhaled Therapies for Lung Diseases at the 2024 American Thoracic Society International Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business Officer
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Participate in Leerink Partners Global Biopharma Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Participate in Multiple Upcoming Investor Conferences
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Participate in the 2023 RBC Capital Markets Healthcare Private Company Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Presents Data from its AP01 and AP02 Inhaled Therapeutics Programs for Pulmonary Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Strengthens Leadership Team with Key Appointments, including Dr. Craig Conoscenti as SVP, Clinical Development, and Jim Bishop as SVP, Business Operations
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Participate in Multiple Upcoming Investor Conferences
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Provide Keynote Presentation at the Formulation & Delivery U.S. 2023 Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Pharma’s CEO Leads Workshop on Clinical Strategy at IPF Summit
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Pharma Presents Data Showing Favorable Tolerability and Potential of AP01 to Preserve Forced Vital Capacity in Adults with Pulmonary Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Pharma Appoints Business Operations Leader, Melissa Rhodes, to the Role of Chief Operating Officer
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Pharma’s Inhaled Pulmonary Fibrosis Programs to be Highlighted at Upcoming ERS International Congress
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Pharma Invited to Present at Canaccord Genuity Annual Growth Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Pharma Highlighting Inhalation Platform at Upcoming H.C. Wainwright and Hanson Wade Conferences in June
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Pharma Made Corporate and Clinical Presentations at ATS 2023 Including Results of Long-Term Treatment of Pulmonary Fibrosis with AP01
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Pharma Showcasing Therapeutic Approach and Clinical Status at ATS 2023 and the Respiratory Innovation Summit (RIS)
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Pharma Presenting at BioEquity Europe
From Avalyn Pharma Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story